Silverleafe Capital Partners’s AbbVie ABBV Stock Holding History

Silverleafe Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$575K	Buy	2,284 +2	+0.1%	+$430	0.16%	58
2026 Q1	$496K	Buy	2,282 +1	+0%	+$222	0.15%	61
2025 Q4	$521K	Buy	2,281 +1	+0%	+$228	0.15%	61
2025 Q3	$528K	Buy	2,280 +44	+2%	+$8.96K	0.16%	53
2025 Q2	$415K	Buy	2,236 +88	+4%	+$16.4K	0.14%	54
2025 Q1	$450K	Buy	2,148 +56	+3%	+$10.9K	0.15%	55
2024 Q4	$372K	Hold	2,092	–	–	0.12%	79
2024 Q3	$413K	Buy	2,092 +2	+0.1%	+$373	0.14%	59
2024 Q2	$358K	Hold	2,090	–	–	0.12%	58
2024 Q1	$381K	Hold	2,090	–	–	0.15%	50
2023 Q4	$324K	Hold	2,090	–	–	0.15%	39
2023 Q3	$312K	Hold	2,090	–	–	0.16%	39
2023 Q2	$282K	Hold	2,090	–	–	0.17%	42
2023 Q1	$333K	Buy	2,090 +17	+0.8%	+$2.6K	0.21%	40
2022 Q4	$335K	Hold	2,073	–	–	0.22%	40
2022 Q3	$278K	Hold	2,073	–	–	0.18%	51
2022 Q2	$318K	Hold	2,073	–	–	0.19%	43
2022 Q1	$336K	Hold	2,073	–	–	0.15%	51
2021 Q4	$281K	Hold	2,073	–	–	0.1%	74
2021 Q3	$224K	Sell	2,073 -12	-0.6%	-$1.37K	0.09%	75
2021 Q2	$235K	Hold	2,085	–	–	0.09%	78
2021 Q1	$226K	Buy	2,085 +12	+0.6%	+$1.28K	0.09%	82
2020 Q4	$222K	Buy	+2,073	New	+$199K	0.1%	69
2020 Q3	–	Sell	-17,430	Closed	-$1.71M	–	65
2020 Q2	$1.71M	Buy	17,430 +13,583	+353%	+$1.2M	1.17%	25
2020 Q1	$293K	Buy	3,847 +134	+4%	+$11.4K	0.35%	30
2019 Q4	$329K	Buy	+3,713	New	+$308K	0.19%	56

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Silverleafe Capital Partners's ABBV Position: Q2 2026 in Review

Silverleafe Capital Partners increased its AbbVie (ABBV) stake by 0.09% in Q2 2026, buying an estimated $430 and bringing the position to 2,284 shares worth $575K. The position accounts for 0.16% of the portfolio, ranked #58.

Silverleafe Capital Partners first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.71M in Q2 2020. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Silverleafe Capital Partners held 2,284 shares of AbbVie worth $575K as of Q2 2026.
Silverleafe Capital Partners bought 2 AbbVie shares in Q2 2026, an estimated $430.
AbbVie made up 0.16% of Silverleafe Capital Partners's portfolio in Q2 2026, its #58 holding.
Silverleafe Capital Partners first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
Silverleafe Capital Partners's AbbVie position peaked at $1.71M in Q2 2020.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Silverleafe Capital Partners's 13F filing for Q2 2026, filed 2 Jul 2026.